Biological markers in breast carcinoma. I. Incidence of abnormalities of CEA, HCG, three polyamines, and three minor nucleosides

D. C. Tormey, T. P. Waalkes, D. Ahmann, C. W. Gehrke, R. W. Zumwatt, J. Snyder, H. Hansen

Research output: Contribution to journalArticle

Abstract

Patients with breast carcinoma were screened for abnormal concentrations of CEA, HCG, putrescine, spermidine, spermine, pseudouridine, N 2, N 2 dimethylguanosine, and 1 methylinosine. Abnormal polyamine levels occurred in less than 15% of the patients. Among the nucleosides, N 2, N 2 dimethylguanosine was the most frequently abnormal, occurring in 57% of the patients with metastatic disease. CEA levels were abnormal in 30% of postoperative N+ patients and 74% of patients with metastatic disease, while HCG elevations were found in 45% and 50%, respectively. All the patients with one or more marker abnormalities could be detected by measuring only CEA, N 2, N 2 dimethylguanosine, and HCG. Among these 3 tests, a singular marker abnormality occurred in 35.8% of the patients, and all 3 tests were abnormal in 21.8% of the patients. The performance of these 3 tests in each patient revealed one or more abnormalities in 97% of the patients with metastatic disease, and 67% of the postoperative N+ patients.

Original languageEnglish (US)
Pages (from-to)1095-1100
Number of pages6
JournalCancer
Volume35
Issue number4
DOIs
StatePublished - 1975
Externally publishedYes

Fingerprint

Polyamines
Nucleosides
Biomarkers
Breast Neoplasms
Incidence
Pseudouridine
Putrescine
Spermidine
Spermine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Biological markers in breast carcinoma. I. Incidence of abnormalities of CEA, HCG, three polyamines, and three minor nucleosides. / Tormey, D. C.; Waalkes, T. P.; Ahmann, D.; Gehrke, C. W.; Zumwatt, R. W.; Snyder, J.; Hansen, H.

In: Cancer, Vol. 35, No. 4, 1975, p. 1095-1100.

Research output: Contribution to journalArticle

Tormey, D. C. ; Waalkes, T. P. ; Ahmann, D. ; Gehrke, C. W. ; Zumwatt, R. W. ; Snyder, J. ; Hansen, H. / Biological markers in breast carcinoma. I. Incidence of abnormalities of CEA, HCG, three polyamines, and three minor nucleosides. In: Cancer. 1975 ; Vol. 35, No. 4. pp. 1095-1100.
@article{8a42c813f24148718dd1f4c043ed4de7,
title = "Biological markers in breast carcinoma. I. Incidence of abnormalities of CEA, HCG, three polyamines, and three minor nucleosides",
abstract = "Patients with breast carcinoma were screened for abnormal concentrations of CEA, HCG, putrescine, spermidine, spermine, pseudouridine, N 2, N 2 dimethylguanosine, and 1 methylinosine. Abnormal polyamine levels occurred in less than 15{\%} of the patients. Among the nucleosides, N 2, N 2 dimethylguanosine was the most frequently abnormal, occurring in 57{\%} of the patients with metastatic disease. CEA levels were abnormal in 30{\%} of postoperative N+ patients and 74{\%} of patients with metastatic disease, while HCG elevations were found in 45{\%} and 50{\%}, respectively. All the patients with one or more marker abnormalities could be detected by measuring only CEA, N 2, N 2 dimethylguanosine, and HCG. Among these 3 tests, a singular marker abnormality occurred in 35.8{\%} of the patients, and all 3 tests were abnormal in 21.8{\%} of the patients. The performance of these 3 tests in each patient revealed one or more abnormalities in 97{\%} of the patients with metastatic disease, and 67{\%} of the postoperative N+ patients.",
author = "Tormey, {D. C.} and Waalkes, {T. P.} and D. Ahmann and Gehrke, {C. W.} and Zumwatt, {R. W.} and J. Snyder and H. Hansen",
year = "1975",
doi = "10.1002/1097-0142(197504)35:4<1095::AID-CNCR2820350412>3.0.CO;2-7",
language = "English (US)",
volume = "35",
pages = "1095--1100",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Biological markers in breast carcinoma. I. Incidence of abnormalities of CEA, HCG, three polyamines, and three minor nucleosides

AU - Tormey, D. C.

AU - Waalkes, T. P.

AU - Ahmann, D.

AU - Gehrke, C. W.

AU - Zumwatt, R. W.

AU - Snyder, J.

AU - Hansen, H.

PY - 1975

Y1 - 1975

N2 - Patients with breast carcinoma were screened for abnormal concentrations of CEA, HCG, putrescine, spermidine, spermine, pseudouridine, N 2, N 2 dimethylguanosine, and 1 methylinosine. Abnormal polyamine levels occurred in less than 15% of the patients. Among the nucleosides, N 2, N 2 dimethylguanosine was the most frequently abnormal, occurring in 57% of the patients with metastatic disease. CEA levels were abnormal in 30% of postoperative N+ patients and 74% of patients with metastatic disease, while HCG elevations were found in 45% and 50%, respectively. All the patients with one or more marker abnormalities could be detected by measuring only CEA, N 2, N 2 dimethylguanosine, and HCG. Among these 3 tests, a singular marker abnormality occurred in 35.8% of the patients, and all 3 tests were abnormal in 21.8% of the patients. The performance of these 3 tests in each patient revealed one or more abnormalities in 97% of the patients with metastatic disease, and 67% of the postoperative N+ patients.

AB - Patients with breast carcinoma were screened for abnormal concentrations of CEA, HCG, putrescine, spermidine, spermine, pseudouridine, N 2, N 2 dimethylguanosine, and 1 methylinosine. Abnormal polyamine levels occurred in less than 15% of the patients. Among the nucleosides, N 2, N 2 dimethylguanosine was the most frequently abnormal, occurring in 57% of the patients with metastatic disease. CEA levels were abnormal in 30% of postoperative N+ patients and 74% of patients with metastatic disease, while HCG elevations were found in 45% and 50%, respectively. All the patients with one or more marker abnormalities could be detected by measuring only CEA, N 2, N 2 dimethylguanosine, and HCG. Among these 3 tests, a singular marker abnormality occurred in 35.8% of the patients, and all 3 tests were abnormal in 21.8% of the patients. The performance of these 3 tests in each patient revealed one or more abnormalities in 97% of the patients with metastatic disease, and 67% of the postoperative N+ patients.

UR - http://www.scopus.com/inward/record.url?scp=0016761047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016761047&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(197504)35:4<1095::AID-CNCR2820350412>3.0.CO;2-7

DO - 10.1002/1097-0142(197504)35:4<1095::AID-CNCR2820350412>3.0.CO;2-7

M3 - Article

C2 - 1116102

AN - SCOPUS:0016761047

VL - 35

SP - 1095

EP - 1100

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -